Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SOAGY and 80,000+ other tickers.
See exactly how SOAGY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SOAGY and 80,000+ other tickers.
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Sartorius Aktiengesellschaft (OTCMKTS:SOAGY - Get Free Report) saw a significant decline in short interest in December. As of December 31st, there was short interest totaling 3,752 shares, a decline of 67.0% from the December 15th total of 11,378 shares. Based on an average trading volume of 6,985 shares, the short-interest ratio is presently 0.5 days.
Sartorius Aktiengesellschaft (OTCPK:SOAGY) Q3 2025 Earnings Call October 16, 2025 7:00 AM EDT Company Participants Petra Muller - Head of Investor Relations Michael Grosse - CEO & Chairman of the Executive Board Florian Funck - CFO & Member of Executive Board Rene Faber - Head of Bioprocess Solutions Division & Member of Executive Board Alexandra Gatzemeyer - Head of the Lab Products & Services Division and Member of Executive Board Conference Call Participants Odysseas Manesiotis - BNP Paribas Exane, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Charles Pitman - Barclays Bank PLC, Research Division Charlie Haywood - BofA Securities, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Douglas Schenkel - Wolfe Research, LLC Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Charles Weston - RBC Capital Markets, Research Division Matthew Weston - UBS Investment Bank, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Harry Gillis - Joh. Berenberg, Gossler & Co. KG, Research Division Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Delphine Le Louet - Sanford C.